Zomedica Corp (ZOM): רווח נקי למניה (EPS TTM)

סמל ולוגו של המותג Zomedica Corporation (ZOM)

Zomedica Corp. proprietary technologies create significant barriers to entry, cementing clinic dependence on consumables. The "razor-and-blade" model provides substantial pricing power through rapid hormone analysis. However, an oligopolistic market and physician conservatism are slowing expansion. The TTM earnings per share trend illustrates business efficiency, while the value of -0.06 captures this metric at its current level.

ZOM (zomedica.com) היסטוריית רווח נקי למניה (EPS TTM) מ-04.07.2022 עד 15.03.2025

ZOM (Zomedica Corp.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

- מחיר מניה ומחיר יעד קונצנזוס:
ניתוח בסיסי של החברה:ZOM - Zomedica Corporation
מוצרים מיוצרים של Zomedica Corporation

An objective valuation of Zomedica Corp. (ZOM) requires a deep analysis of the business's actual profitability. The eps_ttm_co metric measures net income allocated per share over a trailing twelve-month period, reflecting the actual efficiency of capital generation. By analyzing the EPS trend over the last 12 months, an investor can discern the balance between the market price and the asset's intrinsic value. Stable demand for veterinary diagnostics within a defensive sector supports the sustainability of these earnings, confirming the high quality of the issuer's capital.